Zebrafish-based identification of the antiseizure nucleoside inosine from the marine diatom *Skeletonema marinoi*

Théo Brillatz[1]ʘ, Chiara Lauritano[2]ʘ*, Maxime Jacmin[3,4]ʘ, Supitcha Khamma[1], Laurence Marcourt[1], Davide Righi[1], Giovanna Romano[2], Francesco Esposito[2], Adrianna Ianora[2]‡*, Emerson F. Queiroz[1]‡, Jean-Luc Wolfender[1]‡*, Alexander D. Crawford[3,4,5]‡

1 School of Pharmaceutical Sciences, EPGL, University of Geneva, University of Lausanne, Genève, Switzerland, **2** Integrative Marine Ecology Department, Stazione Zoologica Anton Dohrn, Napoli, Italy, **3** Luxembourg Centre for Systems Biomedicine, Université du Luxembourg, Belvaux, Luxembourg, **4** Theracule S.á r.l., Belval, Luxembourg, **5** Faculty of Veterinary Medicine, Norwegian University of Life Sciences, Oslo, Norway

ʘ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* chiara.lauritano@szn.it (CL); jean-luc.wolfender@unige.ch (JLW); adrianna.ianora@szn.it (AI)

Abstract

With the goal of identifying neuroactive secondary metabolites from microalgae, a micro-scale *in vivo* zebrafish bioassay for antiseizure activity was used to evaluate bioactivities of the diatom *Skeletonema marinoi*, which was recently revealed as being a promising source of drug-like small molecules. A freeze-dried culture of *S. marinoi* was extracted by solvents with increasing polarities (hexane, dichloromethane, methanol and water) and these extracts were screened for anticonvulsant activity using a larval zebrafish epilepsy model with seizures induced by the $GABA_A$ antagonist pentylenetetrazole. The methanolic extract of *S. marinoi* exhibited significant anticonvulsant activity and was chosen for bioassay-guided fractionation, which associated the bioactivity with minor constituents. The key anticonvulsant constituent was identified as the nucleoside inosine, a well-known adenosine receptor agonist with previously reported antiseizure activities in mice and rat epilepsy models, but not reported to date as a bioactive constituent of microalgae. In addition, a UHPLC-HRMS metabolite profiling was used for dereplication of the other constituents of *S. marinoi*. Structures of the isolated compounds were elucidated by nuclear magnetic resonance and high-resolution spectrometry. These results highlight the potential of zebrafish-based screening and bioassay-guided fractionation to identify neuroactive marine natural products.

Introduction

Epilepsy is one of the most common neurological disorders, and its unpredictable seizures affect approximately 50 million people of all ages worldwide [1]. Despite the availability of

over 25 approved anti-epileptic drugs (AEDs), a third of treated epileptic patients experience pharmaco-resistance or serious side effects to these medications [2, 3]. There is therefore an urgent need to search for new compounds to treat this disease. An attractive source of novel drug leads for epilepsy are medicinal plants and other natural sources [4].

Here we evaluate extracts from diatoms for potential anticonvulsant activity using an epilepsy bioassay based on zebrafish larvae (*Danio rerio*) [5]. Advantages of this vertebrate model include their small size, rapid development and homology to humans, as well as their suitability for the rapid *in vivo* screening of small molecules for bioactivity [6]. Zebrafish are now well established as a screening platform to rapidly assess the anticonvulsant activity of compounds, using both pharmacological and genetic seizure models. For the seizure assay used for this study, zebrafish larvae were treated with the $GABA_A$ antagonist pentylenetetrazole (PTZ), which induces epileptic seizures that can be quantified both by behavioral analysis and by electrophysiological analysis.

We have recently established zebrafish as a platform for biodiscovery [6–8]. To date, by using zebrafish seizure models for *in vivo* bioassay-guided fractionation, we have isolated several anticonvulsant secondary metabolites from medicinal plant extracts, including bisabolene sesquiterpenoids from the Ayurvedic medicinal plant *Curcuma longa*, tanshinones from the Chinese medicinal plant *Salvia miltiorrhiza* and spirostane glycosides from the Philippine medicinal plant *Solanum torvum* [9–11]. We have also recently highlighted the potential of zebrafish and other *in vivo* models, such as *Caenorhabditis elegans* and *Drosophila*, for marine biodiscovery [12].

Diatoms, with over 100,000 species, constitute one of the major components of marine phytoplankton, comprising up to 40% of annual productivity at sea and representing 25% of global carbon-fixation [13]. Different studies have shown that diatoms are excellent sources of pigments, lipids, carotenoids, ω-3 fatty acids and bioactive compounds [14–19]. Some diatom species have notably demonstrated teratogenic activity against their predators, but also antiproliferative activity against both bacteria and cancer cell lines [20–23]. Diatom extracts have, however, only rarely been investigated for potential neuroprotective and other CNS-relevant bioactivities. Interestingly, the cyclic imine toxin 13-desmethyl spirolide C, a polyketide that targets nicotine receptors, has recently been identified in the dinoflagellate *Alexandrium ostenfeldii* for its potential against Alzheimer disease [24].

The diatom *Skeletonema marinoi* is generally considered as a model species in chemical-ecology studies [25–27], due to its well-known antiproliferative activity on its predators, as well as antimicrobial, anticancer and antioxidant activities [28]. Considering the demonstrated biotechnological and ecological relevance of this species, several studies have been performed or are in progress in order to screen other possible bioactivities and biotechnological applications, as well as to explore ecological aspects [29, 30]. The complete mitochondrial genome of *S. marinoi* has recently been published [31] and the full genome is currently in progress (http://cemeb.science.gu.se/research/target-species-imago/skeletonema-marinoi).

Within the context of a large-scale *in vivo* screening of secondary metabolites from marine microorganisms to identify neuroactive marine natural products [32, 33], extracts of diatoms and other microalgae were screened for neuroactivity using a zebrafish-based behavioral fingerprinting assay [34]. For the antiseizure activity, a zebrafish epilepsy assay was performed based on the proconvulsant PTZ, a $GABA_A$ receptor antagonist [5]. Our subsequent analysis of the methanolic extract of *S. marinoi*, described here, revealed significant anticonvulsant activity. To our knowledge, this is the first report of this type of bioactivity for diatoms. Here we show that the anticonvulsant activity of the diatom *Skeletonema marinoi* is due to the production of the nucleoside inosine, a well-known antiepileptic compound.

Results

Anticonvulsant activity of the *S. marinoi* extracts

The marine diatom *S. marinoi* was tested for potential anticonvulsant activity using the PTZ epilepsy zebrafish model, revealing a reduction of PTZ-induced movement by 62% at 3 µg/mL. In order to better understand the type of compounds responsible for this significant anticonvulsant activity, the freeze-dried culture of *S. marinoi* was extracted by solvents with increasing polarities (hexane, dichloromethane, methanol and distilled water). The anticonvulsant activity of the crude extracts was then submitted again to the zebrafish epilepsy assay (Fig 1). The methanol extract (SM03) revealed the strongest anticonvulsant activity, decreasing PTZ-induced locomotor activity by up to 55% at all the concentrations tested (p<0.001 for both 10 µg/mL and 30 µg/mL and p<0.0001 for 100 µg/mL). The water extract (SM04) also decreased locomotor activity at 10 and 30 µg/mL, while at 100 µg/mL it induced toxicity with an augmentation of fish movements. In contrast, the dichloromethane extract (SM02) was not active and exhibited a significant increase in locomotor activity at the three concentrations tested. The hexane extract (SM01), on the other hand, was toxic for the larvae at 30 and 100 µg/mL.

The most active extract, SM03, did not cause any sign of locomotor impairments in the zebrafish larvae at the maximum tolerated concentration (MTC). For this, an independent and wider series of dilutions were evaluated, from 10 to 300 µg/mL. Anticonvulsant activity was confirmed at 10, 30 and 100 µg/mL. The bioactivity at 200 µg/mL was similar to that observed at 100 µg/mL, while a concentration of 300 µg/mL was found to be toxic for the zebrafish larvae. Due to the clear anticonvulsant activity exhibited by SM03, this extract was submitted to a metabolite profiling and a bioassay-guided isolation in order to identify the compounds responsible for this bioactivity.

Fig 1. Larval locomotor activity (expressed in actinteg units) of *S. marinoi* extracts tested on zebrafish larvae. Hexanic extract (SM01), dichloromethane extract (SM02), methanolic extract (SM03) and aqueous extract (SM04) were tested at 10, 30 and 100 µg/mL concentrations. PTZ was used at 20 mM as the proconvulsant agent. Controls are described as "-" for the vehicle control and "+" for the positive control. Data are represented as Actinteg mean ± SEM (n ≥ 5). Statistical analysis was performed by one-way ANOVA with Dunett's test to compare samples with positive control, with *P* values of <0.001 (***), <0.0001 (****).

Metabolite profiling

In order to obtain an initial insight of the composition of *S. marinoi*, the methanolic extract was submitted to a metabolite profiling by UHPLC-TOF-HRMS. The dereplication gave molecular formula determinations based on HRMS[1] spectra and was cross searched with a custom database built from the Dictionary of Natural Products (DVD version 25:2) [35], with a selection restricted to natural products from cyanobacteria, green and red algae (total of 4043 compounds). This allowed the putative identification of 11 secondary metabolites and to the best of our knowledge, these compounds are here described for the first time in *S. marinoi* (Table 1). Compound (**3**) *m/z* 247.1707 [M+H]⁻, $C_{16}H_{24}O_2$ (Δppm = 0.5) was dereplicated as 10-phenyldecanoic acid [36]; (**4**) *m/z* 489.3075 [M+H]⁻, $C_{25}H_{46}O_9$ (Δppm = 3.0), as a derivative of glycerol 1-(9-hexadecenoate) [37]; (**5**) *m/z* 649.3427 [M+H]⁻, $C_{34}H_{46}N_6O_7$ (Δppm = 10.8), as aeruginosin KT650 [38]; (**6**) *m/z* 249.1869 [M+H]⁻, $C_{16}H_{26}O_2$ (Δppm = 3.7), as 8,11,14-hexadecatrienoic acid or 6,10,14-hexadecatrienoic acid [39]; (**7**) *m/z* 552.2343 [M+H]⁻, $C_{26}H_{47}IO_4$ (Δppm = 1.5), as a iodolactone derivative [40]; (**8**) *m/z* 351.2533 [M+H]⁺, $C_{21}H_{34}O_4$ (Δppm = 2.3), as 9-*O*-methylconstanolactone B [41]; (**9**) *m/z* 329.2668 [M+H]⁺, $C_{19}H_{36}O_4$ (Δppm = 2.0), as ceratodictyol A or B [42]; (**10**) *m/z* 609.2734 [M+H]⁺, $C_{35}H_{36}N_4O_6$ (Δppm = 4.5), as 10-hydroxyphaeophorbide A [43]; (**11**) *m/z* 313.2725 [M+H]⁺, $C_{19}H_{36}O_3$ (Δppm = 3.0), as tetrahydro-2-(1-hydroxy-9-nonenyl)-5-pentyl-3-furanol [44]; (**12**) *m/z* 285.2411 [M+H]⁺, $C_{17}H_{32}O_3$ (Δppm = 4.7), as tanikolide [45]; (**13**) *m/z* 303.2532 [M+H]⁺, $C_{17}H_{34}O_4$ (Δppm = 0.6), as secotanikolide [46]. Isomers were found for (**7**) at a retention time of 15.30 and 15.70 min, (**9**) at 17.45 and 18.01 min, (**10**) at 24.73 and 25.49 min, (**11**) at 21.14 and 21.94 min. The negative ion (NI) ESI-HRMS spectrum of (**1**) displayed an ion at *m/z*

Table 1. Metabolite profiling of SM03 by UHPLC-HRMS. This table indicates putative molecular formula based on HRMS[1] spectra, cross searched with a custom database built from the Dictionary of Natural Products, with a selection restricted to natural products occurring in cyanobacteria, green and red algae.

RT (min)	Isolated as	Dereplicated as	Molecular formula	Organism	Ionization mode (*m/z*)	Error (ppm)	Isotopic pattern score (%)	CRC number	Reference
1.12	Inosine	Inosine (**1**)	$C_{10}H_{12}N_4O_5$	Diatom	[M+H]⁻	3.2			[47]
6.02	Loliolide	Loliolide (**2**)	$C_{11}H_{16}O_3$	Diatom	[M+H]⁺				[48]
15.30		Iodolactone derivative (**7**)	$C_{26}H_{47}IO_4$	Red algae	[M+H]⁻	3.0	90.2	FOW42	[40]
15.65		10-Phenyldecanoic acid (**3**)	$C_{16}H_{24}O_2$	Green algae	[M+H]⁻	0.5	91.4	HPM75 / DFC94	[36]
15.98		Aeruginosin KT650 (**5**)	$C_{34}H_{46}N_6O_7$	Cyanobacteria	[M+H]⁻	10.8	94.7	QQR75	[38]
16.38		8,11,14-Hexadecatrienoic acid or 6,10,14-Hexadecatrienoic acid (**6**)	$C_{16}H_{26}O_2$	Green algae	[M+H]⁻	3.7	97.8	MSG22 / MTB49	[39]
16.52		9-O-Methylconstanolactone B (**8**)	$C_{21}H_{34}O_4$	Red algae	[M+H]⁺	2.3	92.5	NKK80	[41]
17.28		Tanikolide (**12**)	$C_{17}H_{32}O_3$	Cyanobacteria	[M+H]⁺	4.7	95.7	HCY62	[45]
17.45		Ceratodictyol A or Ceratodictyol B (**9**)	$C_{19}H_{36}O_4$	Red algae (associated to a sponge)	[M+H]⁺	2.0	97.9	QFY97 / QFY99	[42]
17.79		Secotanikolide (**13**)	$C_{17}H_{34}O_4$	Cyanobacteria	[M+H]⁺	0.4	94.5	PYQ90	[46]
18.01		Ceratodictyol A or Ceratodictyol B (**9**)	$C_{19}H_{36}O_4$	Red algae (associated to a sponge)	[M+H]⁺	2.0	97.7	QFY97 / QFY99	[42]
19.79		Glycerol 1-(9-hexadecenoate) derivative (**4**)	$C_{25}H_{46}O_9$	Cyanobacteria	[M+H]-	3.0	93.6	CDO10	[37]
21.94		Tetrahydro-2-(1-hydroxy-9-nonenyl)-5-pentyl-3-furanol (**11**)	$C_{19}H_{36}O_3$	Brown algae	[M+H]⁺	3.0	93.0	FOB08	[44]
25.49		10-Hydroxyphaeophorbide A (**10**)	$C_{35}H_{36}N_4O_6$	Green algae (*Chlorella sp.*)	[M+H]⁺	4.5	95.9	BOO46	[43]

https://doi.org/10.1371/journal.pone.0196195.t001

267.0726 [M+H], which is in agreement with the molecular formula $C_{10}H_{12}N_4O_5$ (Δppm = -3.2), while the positive ion (PI) ESI-HRMS spectrum of (**2**), *m/z* 197.1134 [M+H]$^+$, $C_{11}H_{16}O_3$ (Δppm = -18.6). In parallel with the metabolite profiling, this extract was submitted to a one-step preparative chromatography separation after vacuum liquid chromatography (VLC) enrichment to determine if the activity could be linked to one of these metabolites.

Bioassay guided fractionation

The methanolic extract SM03 was first subjected to VLC in order to remove very polar residues (Fig 2A and 2B), and then fractionated by preparative chromatography. For an efficient fractionation, the preparative chromatographic conditions were determined based on a gradient transfer from optimized high-performance liquid chromatography (HPLC) conditions using the same stationary phase (Fig 2C). The fractionation was monitored by UV and

Fig 2. ELSD chromatograms for the methanolic extract before and after enrichment, and its fractionation by preparative chromatography. (A) UHPLC chromatogram of the crude methanolic extract exhibiting mainly unretained polar metabolites. (B) UHPLC metabolite profiling after enrichment by VLC to remove very polar residues. (C) Preparative chromatography for the fractionation of the enriched extract highlighting the isolation of constituent **1**.

evaporative light scattering (ELSD) detectors and led to 158 fractions. Only the 13 richest regions of the chromatogram possessing ELSD peaks (Fig 2C) were selected for evaluation with the zebrafish epilepsy assay, namely fraction A to M (S1 Fig.). A second screening was performed for these fractions to also evaluate the MTC and only fraction B showed a significant decrease of PTZ-induced locomotor activity. In order to confirm its activity, it was evaluated again at different concentrations (10, 50 and 100 µg/mL) and the results were significant for all of the concentrations tested (p<0.01 for 10 and 50 µg/mL, and p<0.05 for 100 µg/mL), with a 56% reduction of the PTZ-induced seizures at 10 µg/mL (Fig 3).

The active fraction was associated with peak (**1**) at a retention time of 10.3 min in the ELSD preparative chromatography trace of the enriched extract (Fig 2C). Analysis of fraction B by UHPLC-HRMS for the metabolite profiling (see 2.2) revealed that the fraction contained a single constituent. The corresponding molecular formula $C_{10}H_{12}N_4O_5$ was searched against entries in the DNP libraries for compounds occurring in cyanobacteria, green and red algae and could not be dereplicated. Nuclear magnetic resonance (NMR) allowed the unambiguous identification of the active compound as inosine (**1**) (S1 Table, S2–S6 Figs). In order to evaluate the quantity of inosine in *S. marinoi* freeze dried pellets, this compound was quantified by NMR indicating a significant amount of inosine (0.19% w/w) [49, 50]. Together with this active compound, the fractionation of SM03 revealed another pure constituent fully characterized as loliolide reported for the first time in *S. marinoi*. Loliolide was not active in the zebrafish epilepsy model.

Discussion

The marine environment represents a significant reservoir for the discovery of new drugs because of its vast chemical and biological diversity. Compounds with neuroprotective and anticonvulsant activities have been found in both marine macro- and microorganisms [26, 51–55]. Examples of marine natural products with anticonvulsant activities are ceramides from the Red Sea sponge *Negombata corticata* [51], a nonsteroidal sesterterpene manoalide from the marine sponge *Luffariella variabilis* [53], semi-purified fractions from the sponge *Spongia officinalis* [52], conantokin-R from the venoms of marine cone snails [54] and a farnesylacetone epoxide from the brown macroalga *Cystophora moniliformis* [55]. Regarding microalgae, a cyclic imine toxin, 13-desmethyl spirolide C from the dinoflagellate *Alexandrium ostenfeldii*, showed potential activity against Alzheimer disease [26], but to date no CNS-active compounds have been reported from diatoms.

Here, we report the anticonvulsant activity of secondary metabolite extracts of the marine diatom *Skeletonema marinoi* and the identification of an active anticonvulsant constituent, inosine. Solvents with increasing polarities (hexane, dichloromethane, methanol and water) were used to obtain extracts with different metabolite profiles. The methanolic extract, generally used for the extraction of polar compounds [56], showed the strongest significant anticonvulsant activity, reducing seizure-related movement activity in PTZ-treated zebrafish larvae by 55% at 100µg/ml. This PTZ seizure model was then used for zebrafish bioassay-guided fractionation [5, 11] of the diatom extract, resulting in the isolation of inosine, which inhibited PTZ-induced seizures by 56% at 10 µg/ml [35, 57, 58].

Inosine, as well as adenosine and some other non-adenosine nucleosides (e.g. guanosine and uridine), are known to be modulatory molecules in the central nervous system, regulating various physiological and pathophysiological processes in the brain, such as sleep and epileptic seizures [59]. Indeed, Kovács and colleagues highlighted that cerebral spinal fluid levels of purine nucleosides (adenosine, guanosine and inosine) are altered after a single seizure episode and suggested that purine nucleosides have an important role in terminating seizures [60]. In addition, these studies reported that inosine exerts its anticonvulsant effects by acting on benzodiazepine binding

Fig 3. Effects of inosine on larval locomotor activity after 30 min tracking period (expressed in actinteg). Inosine (1) was tested at 10, 50 and 100 μg/mL. PTZ was used at 20 mM as proconvulsant agent. Controls are indicated as "-" for the vehicle control and "+" for the positive control. Data are represented as Actinteg mean ± SEM (n ≥ 3). Statistical analysis was performed by one-way ANOVA with Dunett's test to compare samples with positive control, with P values of <0.05 (*), <0.01 (**).

sites in $GABA_A$ receptors. Consequently, inosine was shown to increase the latency of PTZ-induced locomotor activity in mice and rat models [61]. Finally, inosine reached phase III clinical trials (USA, NCT02642393) for the study of urate elevation in Parkinson's disease and phase II for the treatment of ALS (USA, NCT02288091) [62, 63]. In this work, we could demonstrate the validity of the PTZ-treated zebrafish larvae model for screening extracts from marine origin and for the efficient identification of their anticonvulsant metabolites.

Materials and methods

General experimental procedure

NMR ^{1}H and ^{13}C spectroscopic data were recorded on a Varian (Palo Alto, CA, USA) Unity Inova 500 MHz spectrometer. Chemical shifts (δ) are measured in parts per million (ppm)

using the CD$_3$OD signal as internal standard for all spectra (δ_H 3.31; δ_C 49.0), and coupling constants (*J*) are reported in Hz. Complete assignment was performed based on two-dimensional experiments (COSY, NOESY, HSQC and HMBC). High resolution mass spectrometry data were obtained on a Micromass LCT Premier Time-Of-Flight (TOF) mass spectrometer from Waters with an electrospray ionization (ESI) interface (Waters, Milford, MA). Reverse phase analyses were first performed on a high-performance liquid chromatography (HPLC) Agilent 1260 Infinity II LC system consisting of a degasser, a mixing pump, an autosampler, and a diode array detector (PDA) (Agilent Technologies, Santa Clara, USA) connected to an evaporative light scattering detector (ELSD) Sedex LT-ELSD 85 (Sedere, Oliver, France). Fractionation was performed on a Puriflash 4250 preparative chromatographic system (Interchim, Montluçon Cedex, France) equipped with a quaternary pump, a photodiode array detector, and a fraction collector.

Cell culturing and harvesting

Seventeen different replicates of the centric diatom *S. marinoi* (clone FE6 from the Stazione Zoologica culture collection previously identified with both microscopy and 18S ribosomal sequencing) were cultured in Guillard's f/2 medium in ten-liter polycarbonate carboys. *S. marinoi* cultures were constantly bubbled with air filtered through 0.2 μm membrane filters and kept in a climate chamber at 19˚C and a 12:12 hours light:dark cycle (100 μmol photons m^{-2}. s^{-1}) [64]. Initial cell concentrations were about 5000 cells/mL; culture growth was monitored daily by fixing 1 ml of culture with one drop of Lugol (final concentration of about 2%) and counting cells in a Bürker counting chamber under an Axioskop 2 microscope (20×) (Carl Zeiss GmbH, Jena, Germany). At the end of the stationary phase, cultures were centrifuged for 15 min at 4˚C at 3900 g using a cooled centrifuge with a swing-out rotor (DR 15P, Braun Biotechnology International, Allentown, PA, USA). The supernatant was discarded and pellets were freeze-dried and kept at −80˚C until chemical extraction.

Preparation of extracts and fractionation

Freeze dried pellets of *S. marinoi* were pooled together and ground under liquid nitrogen to avoid degradation. A successive extraction by solvents with increasing polarities (hexane, dichloromethane, methanol and water respectively) was performed under agitation on the *S. marinoi* powder (9.17 g). Each extract was concentrated under vacuum (Büchi Rotavapor) and then dried with a nitrogen flow until complete evaporation of solvent. The extractions afforded 0.50 g of hexane (5.45%), 0.48 g of dichloromethane (5.23%), 4.16 g of methanol (45.37%) and 2.02 g of aqueous (22.03%) extracts. Samples were named as hexane (SM01), dichloromethane (SM02), methanol (SM03) and aqueous (SM04) extracts. The methanolic extract (4.16 g) was subjected to a VLC in order to remove very polar compounds. A 250 mL sintered-glass Büchner funnel attached to a vacuum line was packed with a C18 reverse phase LiChroprep® 40–63 μm (Lobar® Merck, Darmstadt, Germany). The stationary phase was first conditioned with methanol (4 x 250 mL) followed by distilled water (4 x 250 mL). The dry load was prepared by mixing 4.16 g of the extract with 5 g of C18 reverse phase LiChroprep® 40–63 μm (Lobar® Merck, Darmstadt, Germany). The mixture was introduced from the top of the VLC by dry load for uniform loading. Elution of the sample was performed using water (4 x 250 mL) followed by methanol (4 x 250 mL) and was washed with ethyl acetate (4 x 250 mL). This yielded the following VLC fractions: SM03_VLC_H$_2$O (1.50 g), SM03_VLC_MeOH (0.53 g) and SM03_VLC_EtOAc (0.46 g). The VLC methanolic fraction was then separated by preparative chromatography.

HPLC-PDA-ELSD analysis

Extracts and fractions were analyzed by HPLC with UV and ELSD detection on a X-Bridge C18 column (250 x 4.6 mm i.d., 5 μm; Waters, Milford, MA, USA) using a mobile phase consisting of water (A) and methanol (B) containing both 0.1% formic acid; separation was performed with a linear gradient from 5 to 95% of B in 40 min; Injection volume was set at 10 μL, the flow rate was fixed at 1 mL/min. The samples were diluted in methanol at 5 mg/mL. ELSD conditions: 55˚C, 3.1 bar N_2 and gain 8.

UHPLC-TOF-HRMS analysis

Ultra high-performance liquid chromatography coupled to Time of Flight (UHPLC-TOF) high resolution mass spectrometry was used to monitor extracts, fractions and pure compounds. The instrument used was a Waters® Acquity UPLC system coupled to a Waters® Micromass LCT Premier Time-Of-Flight (TOF) mass spectrometer (Waters, Milford MA, USA) equipped with an electrospray interface (ESI). ESI conditions were as follow: capillary voltage: 2400 V; cone voltage: 40 V; source temperature: 120˚C; desolvation temperature: 300˚C; cone gas flow 20 L/h; desolvation gas flow 600 L/h; MCP detector voltage: 2.4 kV; positive mode: 2.8 kV and negative mode: 2.4 kV. Detection was performed in positive ion mode (PI) and in negative ion mode (NI) with a m/z range of 100–1300 Da and a scan time of 0.3 sec in the centroid mode. The mass spectrometer was calibrated using sodium formate, and leucine encephalin. UHPLC analysis were performed on a Acquity UPLC System (Waters, Milford MA, USA) using a Acquity BEH C18 column (1 x 50 mm; 1.7 μm; Waters, Milford, MA, USA). The temperatures in the auto sampler and in the column oven were fixed at 10 and 40˚C, respectively. The mobile phase consisted of water (A) and acetonitrile (B) containing both 0.1% formic acid; separation was performed with a linear gradient from 5% to 95% of B in 4 min followed by a 0.8 min isocratic step at 95% of B and then 1.2 min isocratic step at 5% of B for column reconditioning. Injection volume was set at 1 μL, the flow rate was fixed at 0.46 mL/min. The samples were diluted in methanol at 100 μg/mL.

Fractionation of the VLC methanolic fraction

The optimized analytical HPLC conditions were geometrically transferred for fractionation on a Puriflash 4250 preparative chromatographic system (Interchim, Montluçon Cedex, France) equipped with a quaternary pump, a UV and a ELSD detectors, and a fraction collector [65]. The separation was performed using a HQ C18 column (PF-C18/120 g, 15 μm; Interchim, Montluçon Cedex, France) with water (A) and methanol (B) containing both 0.1% formic acid as mobile phase. The separation was achieved using a step gradient from 5 to 85% of B in 21 min and then 85 to 100% of B in 19 min. The flow rate was fixed at 26 mL/min. The UV detection in the scan mode (200–600 nm) and ELSD (35˚C, gain 8, 3.5 bar, 1 mL/min). The separation afforded 158 fractions which were dried under a GeneVac HT-4X Series II system (Genevac Limited, UK). Selection of fractions for screening in the zebrafish epilepsy assay was performed by using the intensity of the ELSD signal detection. Using this approach, compound **1** (4.4 mg) was isolated from fraction B.

NMR spectral data and quantification of inosine

Inosine (1). White amorphous powder. ^{1}H NMR (CD$_3$OD, 500 MHz) δ 3.76 (2H, dd, J = 3.2; 12.3 Hz, H-5'), 3.88 (2H, dd, J = 3.2; 12.3 Hz, H-5'), 4.15 (1H, q, J = 3.2 Hz, H-4'), 4.33 (1H, dd, J = 3.5; 5.2 Hz, H-3'), 4.64 (1H, t, J = 5.7 Hz, H-2'), 6.03 (1H, d, J = 5.7 Hz, H-1'), 8.08 (1H, s, H-2), 8.35 (1H, s, H-8). ^{13}C NMR (CD$_3$OD, 126 MHz) δ 62.4 (C-5'), 87.3 (C-4'), 71.6

(C-3'), 75.3 (C-2'), 90.4 (C-1'), 124.7 (C-5), 140.8 (C-8), 146.6 (C-2), 148.0 (C-4), 157.1 (C-6). ESI-HRMS m/z 268.0704 [M + H]$^-$ (calculated for $C_{10}H_{12}N_4O_5$, 268.0729).

Quantification of inosine. The quantification of (**1**) by ^{1}H NMR was performed on a Bruker Avance III HD 600 MHz NMR spectrometer equipped with a QCI 5 mm Cryoprobe (Bruker BioSpin, Rheinstetten, Germany) (600.17 MHz). The ^{1}H NMR spectra was recorded in a deuterated phosphate buffer solution (88.7 mM KH_2PO_4, pH 7 in D_2O) containing 578.2 μM of TSP (3-(trimethylsilyl)propionic-2,2,3,3-d$_4$ acid sodium). TSP was then used as the chemical shift reference (δ_H 0.0) and as the internal reference standard for quantification. The result was expressed as a percentage (w/w, dry weight).

Zebrafish breeding and maintenance

Adult zebrafish (AB strain) were raised at 28°C on a 14/10 hours light/dark cycle according to standard aquaculture conditions [66]. Eggs were collected following natural spawning, sorted and reared in an embryo medium containing 0.3x of Danieau's solution (1.5 mM HEPES, pH 7.6, 17.4 mM NaCl, 0.21 mM KCl, 0.12 mM $MgSO_4$, and 0.18 mM $Ca(NO_3)_2$ under constant light conditions in an incubator set at 28°C until six or seven days post fertilization (dpf). Sorting of zebrafish embryos and larvae (based on phenotype and swimming behavior) and medium refreshment were performed daily until seven dpf. Upon completion of the zebrafish experiments reported here, all zebrafish larvae were immediately euthanized following regulatory guidelines. All zebrafish experiments performed in this study were approved by the Ethics Committee of the University of Luxembourg. In the experimental protocol reported here, PTZ-induced activity were used to evaluate the potential antiseizure activity of extracts/fractions/compounds within a defined time window. Based on the MTC of the tested samples, no appreciable levels of suffering were predicted nor observed that would require (a) monitoring for humane endpoints and/or (b) early euthanasia.

Determination of the maximum tolerated concentration (MTC) in zebrafish larvae

To determine the range of appropriate concentrations tested in zebrafish for the evaluation of anticonvulsant activity before toxic signs, zebrafish larvae were incubated at different concentrations (10, 30, 100, 200 and 300 μg/mL) of samples dissolved in 1 mL of embryo medium (at a final DMSO concentration of 1%). The larvae were examined after 18 hours of incubation time and compared to the control group to detect the following signs of toxicity: absence of startle response to plate taps, presence of edema, loss of posture, paralysis and death. Thus, the MTC was defined as the highest concentration at which no signs of toxicity were observed in all replicates tested for one concentration.

Evaluation of anticonvulsant activity in the zebrafish seizure models

Zebrafish larvae from six or seven dpf were monitored using the View Point Video Track System for Zebrafish™ (Version 2.3.1.0, ViewPoint, France) [5]. The system consisted in an infrared light source, a high resolution digital video camera to capture larval movements within a defined time period (30 min in our experimental set-up) and the software to analyze larval locomotor activity. The highest concentrations of the samples tested correspond to the previously determined MTC values. Zebrafish larvae were placed in a flat bottom 96-well plate (Falcon®, USA) (1 larvae/well, at least 3 replicates for each concentration tested, e.g. 10, 30, 50 and 100, 200, 300 μg/mL) and incubated at 28°C for 18 hours (as performed in [5]). Larvae medium added to DMSO (1% w/v) was used as the vehicle control. Pentylenetetrazole (PTZ) added to the vehicle at 20 mM served as positive control. PTZ added to the medium elicits

distinct seizure-like behaviors characterized by greatly increased locomotor activity (Stage I) and "whirlpool-like" circling swim behavior (Stage II). Thus, normal locomotor activity and seizures could have been differentiated by seeing a significant increased ratio between movement with vehicle only and vehicle with PTZ. Moreover, each tracking experiment has been videotaped as part of this research and fish seizures has been determined based on the "whirlpool-like" swimming behavior (Stage II seizure) [67]. The toxicity of methanol in 6–7 dpf larvae have been studied by Maes et al. who assessed a 2% tolerance to this solvent [68]. Movements of fish larvae were recorded for 30 min with an automated video-tracking from ViewPoint®. Then, PTZ solution was added in each well (except the negative control). Video-tracking of larval movements commenced exactly 5 min after addition of PTZ solution to the wells and was recorded again for 30 min. Data were saved by the software (Viewpoint®) each 5 min as an average value until 30 min of total larval movements. Results were interpreted in actinteg and time units [5]. Actinteg unit is determined by the sum of pixel shifts detected for each larva during the reported time period (e.g. 30 min).

Statistical analysis

Data were expressed as mean ± SEM (n ≥ 3). Statistical differences among the data were assessed by a one-way ANOVA with Dunett's test to compare samples with positive control, with *P* values of <0.05 (*), <0.01 (**), <0.001 (***), <0.0001 (****). Analyses were performed using the statistical software Prism v7.02 (GraphPad Software).

Conclusions

This study describes a zebrafish-based screening for neuroactivity and antiseizure activity of *Skeletonema marinoi*, a marine diatom which has previously shown antimicrobial, anticancer and antioxidant activities [28, 69]. The bioassay-guided investigation of its methanolic extract led to the isolation of the bioactive nucleoside inosine, which significantly reduced PTZ-induced locomotor activity in a zebrafish epilepsy assay. Inosine is reported here for the first time in *S. marinoi*. We also report 11 other metabolites described in the UHPLC-TOF-HRMS profiling, thereby further documenting the chemical composition of *S. marinoi*. This study demonstrates the potential of marine diatoms as a source of anticonvulsant compounds.

Supporting information

S1 Fig. Larval locomotor activity (expressed in actinteg units) of the 13 richest fractions from the ELSD chromatogram after fractionation by preparative chromatography. (A) Fractions A to D. (B) Fractions E to I. (C) Fractions J to M. Fractions are tested at 10, 30 and 100 µg/mL and data are represented as actinteg mean ± SEM (n ≥ 3). PTZ was used at 20 mM as the proconvulsant agent. Controls are described as "-" for the vehicle control and "+" for the positive control.
(PDF)

S2 Fig. Correlations of inosine with COSY (blue bonds) and HMBC (black arrows) (500 MHz, CD₃OD).
(PDF)

S3 Fig. ¹H NMR (500 MHz, CD₃OD) spectrum of inosine.
(PDF)

S4 Fig. COSY NMR (500 MHz, CD₃OD) spectrum of inosine.
(PDF)

S5 Fig. HSQC NMR (500 MHz, CD₃OD) spectrum of inosine.
(PDF)

S6 Fig. HMBC NMR (500 MHz, CD₃OD) spectrum of inosine.
(PDF)

S1 Table. ¹H and ¹³C NMR assignments of inosine (500 MHz, CD₃OD).
(PDF)

Acknowledgments

Author Contributions

Conceptualization: Théo Brillatz, Chiara Lauritano, Giovanna Romano, Adrianna Ianora, Emerson F. Queiroz, Alexander D. Crawford.

Data curation: Théo Brillatz, Chiara Lauritano, Maxime Jacmin, Supitcha Khamma.

Formal analysis: Théo Brillatz, Chiara Lauritano, Maxime Jacmin, Supitcha Khamma, Laurence Marcourt, Emerson F. Queiroz.

Methodology: Théo Brillatz, Chiara Lauritano, Davide Righi, Francesco Esposito.

Writing – original draft: Théo Brillatz, Chiara Lauritano.

Writing – review & editing: Théo Brillatz, Chiara Lauritano, Adrianna Ianora, Emerson F. Queiroz, Jean-Luc Wolfender, Alexander D. Crawford.

References

1. Megiddo I, Colson A, Chisholm D, Dua T, Nandi A, Laxminarayan R. Health and economic benefits of public financing of epilepsy treatment in India: An agent-based simulation model. Epilepsia. 2016; 57 (3):464–74. https://doi.org/10.1111/epi.13294 PMID: 26765291

2. Wahab A. Difficulties in treatment and management of epilepsy and challenges in new drug development. Pharmaceuticals. 2010; 3(7):2090–110. https://doi.org/10.3390/ph3072090 PMID: 27713344

3. Santulli L, Coppola A, Balestrini S, Striano S. The challenges of treating epilepsy with 25 antiepileptic drugs. Pharmacol Res. 2016; 107:211–9. https://doi.org/10.1016/j.phrs.2016.03.016 PMID: 26995307

4. Schachter SC. Botanicals and Herbs: A traditional approach to treating epilepsy. Neurotherapeutics. 2009; 6(2):415–20. https://doi.org/10.1016/j.nurt.2008.12.004 PMID: 19332338

5. Afrikanova T, Serruys AS, Buenafe OE, Clinckers R, Smolders I, de Witte PA, et al. Validation of the zebrafish pentylenetetrazol seizure model: locomotor versus electrographic responses to antiepileptic drugs. Plos One. 2013; 8(1):e54166. https://doi.org/10.1371/journal.pone.0054166 PMID: 23342097

6. Crawford AD, Esguerra CV, de Witte PAM. Fishing for drugs from nature: Zebrafish as a technology platform for natural product discovery. Planta Med. 2008; 74(6):624–32. https://doi.org/10.1055/s-2008-1034374 PMID: 18584811

7. Vermoesen K, Serruys ASK, Loyens E, Afrikanova T, Massie A, Schallier A, et al. Assessment of the convulsant liability of antidepressants using zebrafish and mouse seizure models. Epilepsy Behav. 2011; 22(3):450–60. https://doi.org/10.1016/j.yebeh.2011.08.016 PMID: 21962757

8. Challal S, Bohni N, Buenafe OE, Esguerra CV, de Witte PA, Wolfender JL, et al. Zebrafish bioassay-guided microfractionation for the rapid *in vivo* identification of pharmacologically active natural products. Chimia. 2012; 66(4):229–32. https://doi.org/10.2533/chimia.2012.229 PMID: 22613156

9. Orellana-Paucar AM, Serruys AS, Afrikanova T, Maes J, De Borggraeve W, Alen J, et al. Anticonvulsant activity of bisabolene sesquiterpenoids of *Curcuma longa* in zebrafish and mouse seizure models. Epilepsy Behav. 2012; 24(1):14–22. https://doi.org/10.1016/j.yebeh.2012.02.020 PMID: 22483646

10. Buenafe OE, Orellana-Paucar A, Maes J, Huang H, Ying X, De Borggraeve W, et al. Tanshinone IIA exhibits anticonvulsant activity in zebrafish and mouse seizure models. ACS Chem Neurosci. 2013; 4 (11):1479–87. https://doi.org/10.1021/cn400140e PMID: 23937066

11. Challal S, Buenafe OE, Queiroz EF, Maljevic S, Marcourt L, Bock M, et al. Zebrafish bioassay-guided microfractionation identifies anticonvulsant steroid glycosides from the Philippine medicinal plant *Solanum torvum*. ACS Chem Neurosci. 2014; 5(10):993–1004. https://doi.org/10.1021/cn5001342 PMID: 25127088

12. West KHJ, Crawford AD. Marine Biodiscovery Goes Deeper: Using *in vivo* bioassays based on model organisms to identify biomedically relevant marine metabolites. Planta Med. 2016; 82(9–10):754–60. https://doi.org/10.1055/s-0042-106391 PMID: 27191583

13. Falkowski PG. The role of phytoplankton photosynthesis in global biogeochemical cycles. Photosynth Res. 1994; 39(3):235–58. https://doi.org/10.1007/BF00014586 PMID: 24311124

14. Romano G, Costantini M, Sansone C, Lauritano C, Ruocco N, Ianora A. Marine microorganisms as a promising and sustainable source of bioactive molecules. Mar Environ Res. 2016.

15. Yuan JP, Peng J, Yin K, Wang JH. Potential health-promoting effects of astaxanthin: a high-value carotenoid mostly from microalgae. Mol Nutr Food Res. 2011; 55(1):150–65. https://doi.org/10.1002/mnfr.201000414 PMID: 21207519

16. Bozarth A, Maier UG, Zauner S. Diatoms in biotechnology: modern tools and applications. Appl Microbiol Biotechnol. 2009; 82(2):195–201. https://doi.org/10.1007/s00253-008-1804-8 PMID: 19082585

17. Fontana A, d'Ippolito G, Cutignano A, Miralto A, Ianora A, Romano G, et al. Chemistry of oxylipin pathways in marine diatoms. Pure Appl Chem. 2007; 79(4):481–90.

18. Lauritano C, Martín J, de la Cruz M, Reyes F, Romano G, Ianora A. First identification of marine diatoms with anti-tuberculosis activity. Sci Rep. 2018; 8(1):2284. https://doi.org/10.1038/s41598-018-20611-x PMID: 29396507

19. Lauritano C, Ianora A. Marine Organisms with anti-diabetes properties. Mar Drugs. 2016; 14(12):220.

20. Caldwell GS. The influence of bioactive oxylipins from marine diatoms on invertebrate reproduction and development. Mar Drugs. 2009; 7(3):367–400. https://doi.org/10.3390/md7030367 PMID: 19841721

21. Sushanth VR, Rajashekhar M. Antioxidant and antimicrobial activities in the four species of marine microalgae isolated from Arabian Sea of Karnataka Coast. Indian J Geo-Mar Sci. 2015; 44(1):69–75.

22. Naviner M, Berge JP, Durand P, Le Bris H. Antibacterial activity of the marine diatom *Skeletonema costatum* against aquacultural pathogens. Aquaculture. 1999; 174(1–2):15–24.

23. Desbois AP, Lebl T, Yan LM, Smith VJ. Isolation and structural characterisation of two antibacterial free fatty acids from the marine diatom, *Phaeodactylum tricornutum*. Appl Microbiol Biot. 2008; 81(4):755–64.

24. Stivala CE, Benoit E, Araoz R, Servent D, Novikov A, Molgó J, et al. Synthesis and biology of cyclic imine toxins, an emerging class of potent, globally distributed marine toxins. Nat Prod Rep. 2015; 32 (3):411–35. https://doi.org/10.1039/c4np00089g PMID: 25338021

25. Lauritano C, Orefice I, Procaccini G, Romano G, Ianora A. Key genes as stress indicators in the ubiquitous diatom *Skeletonema marinoi*. Bmc Genomics. 2015; 16:411. https://doi.org/10.1186/s12864-015-1574-5 PMID: 26018764

26. Carotenuto Y, Dattolo E, Lauritano C, Pisano F, Sanges R, Miralto A, et al. Insights into the transcriptome of the marine copepod *Calanus helgolandicus* feeding on the oxylipin-producing diatom *Skeletonema marinoi*. Harmful Algae. 2014; 31:153–62. https://doi.org/10.1016/j.hal.2013.11.002 PMID: 28040104

27. Lauritano C, Carotenuto Y, Vitiello V, Buttino I, Romano G, Hwang JS, et al. Effects of the oxylipin-producing diatom *Skeletonema marinoi* on gene expression levels of the calanoid copepod *Calanus sinicus*. Mar Genomics. 2015; 24 Pt 1:89–94.

28. Lauritano C, Andersen JH, Hansen E, Albrigtsen M, Escalera L, Esposito, et al. Bioactivity screening of microalgae for antioxidant, anti-inflammatory, anticancer, anti-diabetes, and antibacterial activities. Front Mar Sci. 2016; 3(68).

29. Sefbom J, Sassenhagen I, Rengefors K, Godhe A. Priority effects in a planktonic bloom-forming marine diatom. Biol Lett. 2015; 11(5):20150184. https://doi.org/10.1098/rsbl.2015.0184 PMID: 25948569

30. Orefice I, Lauritano C, Procaccini G, Ianora A, Romano G. Insights into possible cell-death markers in the diatom *Skeletonema marinoi* in response to senescence and silica starvation. Mar Genom. 2015; 24(1):81–8.

31. An SM, Kim SY, Noh JH, Yang EC. Complete mitochondrial genome of *Skeletonema marinoi* (Mediophyceae, Bacillariophyta), a clonal chain forming diatom in the west coast of Korea. Mitochondrial DNA. 2017; 28(1):19–20. https://doi.org/10.3109/19401736.2015.1106523 PMID: 26641316

32. Jaspars M, De Pascale D, Andersen JH, Reyes F, Crawford AD, Ianora A. The marine biodiscovery pipeline and ocean medicines of tomorrow. J Mar Biol Assoc Uk. 2016; 96(1):151–8.

33. Long SM, Liang FY, Wu Q, Lu XL, Yao XL, Li SC, et al. Identification of marine neuroactive molecules in behaviour-based screens in the larval zebrafish. Mar Drugs. 2014; 12(6):3307–22. https://doi.org/10.3390/md12063307 PMID: 24886868

34. Kokel D, Bryan J, Laggner C, White R, Cheung CYJ, Mateus R, et al. Rapid behavior-based identification of neuroactive small molecules in the zebrafish. Nat Chem Biol. 2010; 6(3):231–7. https://doi.org/10.1038/nchembio.307 PMID: 20081854

35. Dictionary of Natural Products. http://dnp.chemnetbase.com/].

36. Paschke RF, Wheeler DH. The unsaturated fatty acids of the alga *chlorella*. Journal of the American Oil Chemists' Society. 1954; 31(3):81–5.

37. Rho MC, Matsunaga K, Yasuda K, Ohizumi Y. A novel inhibitor of platelet aggregation from the Cyanophyceae *Oscillatoria rosea* (NIES-208). Planta Med. 1996; 62(5):473–4. https://doi.org/10.1055/s-2006-957944 PMID: 8923815

38. Lifshits M, Carmeli S. Metabolites of *Microcystis aeruginosa* bloom material from lake Kinneret, Israel. J Nat Prod. 2012; 75(2):209–19. https://doi.org/10.1021/np200909x PMID: 22280481

39. Della Greca M, Monaco P, Pinto G, Pollio A, Previtera L. Lipid composition of the acidophilic alga *Dunaliella acidophila*. II. Molecular species of galactolipids. Biochim Biophys Acta—Lipids and Lipid Metabolism. 1989; 1004(2):271–3.

40. Su JY, Xu XH, Zeng LM, Wang CJ. A new iodolactone from *Laurencia majuscula*. Chem J Chin Univ. 1997; 18:1333.

41. Nagle DG, Gerwick WH. Structure and stereochemistry of constanolactones A-G, lactonized cyclopropyl oxylipins from the red marine alga *Constantinea simplex*. J Org Chem. 1994; 59(24):7227–37.

42. Akiyama T, Ueoka R, van Soest RWM, Matsunaga S. Ceratodictyols, 1-glyceryl ethers from the red alga−sponge association *Ceratodictyon spongiosum/Haliclona cymaeformis*. J Nat Prod. 2009; 72 (8):1552–4. https://doi.org/10.1021/np900355m PMID: 19670881

43. Endo H, Hosoya H, Koyama T, Ichioka M. Isolation of 10-Hydroxypheophorbide A as a photosensitizing pigment from alcohol-treated *Chlorella* Cells. Agric Biol Chem. 1982; 46(9):2183–93.

44. Chikashita H, Nakamura Y, Uemura H, Itoh K. The cyclodehydration route to the asymmetric total synthesis of the marine natural product isolated from the brown alga, *Notheia Anomala*. Chem Lett. 1993; 22(3):477–80.

45. Singh IP, Milligan KE, Gerwick WH. Tanikolide, a toxic and antifungal lactone from the marine cyanobacterium *Lyngbya majuscula*. J Nat Prod. 1999; 62(9):1333–5. PMID: 10514329

46. Gutierrez M, Andrianasolo EH, Shin WK, Goeger DE, Yokochi A, Schemies J, et al. Structural and synthetic investigations of tanikolide dimer, a SIRT2 selective inhibitor, and tanikolide seco-acid from the Madagascar marine cyanobacterium *Lyngbya majuscula*. J Org Chem. 2009; 74(15):5267–75. https://doi.org/10.1021/jo900578j PMID: 19572575

47. Skolnick P, Syapin PJ, Paugh BA, Moncada V, Marangos PJ, Paul SM. Inosine, an endogenous ligand of the brain benzodiazepine receptor, antagonizes pentylenetetrazole-evoked seizures. Proc Natl Acad Sci USA. 1979; 76(3):1515–8. PMID: 286337

48. Hodges R, Porte AL. The structure of loliolide. Tetrahedron. 1964; 20(6):1463–7.

49. Holzgrabe U. Quantitative NMR spectroscopy in pharmaceutical applications. Prog Nucl Magn Reson Spectrosc. 2010; 57(2):229–40. https://doi.org/10.1016/j.pnmrs.2010.05.001 PMID: 20633364

50. Pauli GF, Chen S-N, Simmler C, Lankin DC, Gödecke T, Jaki BU, et al. Importance of purity evaluation and the potential of quantitative 1H NMR as a purity assay. J Med Chem. 2014; 57(22):9220–31. https://doi.org/10.1021/jm500734a PMID: 25295852

51. Ahmed SA, Khalifa SI, Hamann MT. Antiepileptic ceramides from the Red Sea sponge *Negombata corticata*. J Nat Prod. 2008; 71(4):513–5. https://doi.org/10.1021/np0703287 PMID: 18355032

52. Dellai A, Ben Mansour H, Clary-Laroche A, Deghrigue M, Bouraoui A. Anticonvulsant and analgesic activities of crude extract and its fractions of the defensive secretion from the Mediterranean sponge, *Spongia officinali*s. Cancer Cell Int. 2012; 12.

53. Dorandeu F, Hesters W, Girard F, Four E, Foquin A, Bon C, et al. Inhibition of crotoxin phospholipase A (2) activity by manoalide associated with inactivation of crotoxin toxicity and dissociation of the heterodimeric neurotoxic complex. Biochem Pharmacol. 2002; 63(4):755–61. PMID: 11992645

54. Jimenez EC, Donevan S, Walker C, Zhou LM, Nielsen J, Cruz LJ, et al. Conantokin-L, a new NMDA receptor antagonist: determinants for anticonvulsant potency. Epilepsy Res. 2002; 51(1–2):73–80. PMID: 12350383

55. Spence I, Jamieson DD, Taylor KM. Anticonvulsant activity of farnesylacetone epoxide-a novel marine natural product. Experientia. 1979; 35(2):238–9. PMID: 217722

56. Pandey A, Tripati S. Concept of standardization, extraction and pre phytochemical screening strategies for herbal drug. J Pharmacogn Phytochem. 2014; 2(5):115–9.

57. Ganzella M, Faraco RB, Almeida RF, Fernandes VF, Souza DO. Intracerebroventricular administration of inosine is anticonvulsant against quinolinic acid-induced seizures in mice: an effect independent of benzodiazepine and adenosine receptors. Pharmacol Biochem Behav. 2011; 100(2):271–4. https://doi.org/10.1016/j.pbb.2011.09.001 PMID: 21945561

58. Prestegard SK, Oftedal L, Coyne RT, Nygaard G, Skjaerven KH, Knutsen G, et al. Marine benthic diatoms contain compounds able to induce leukemia cell death and modulate blood platelet activity. Mar Drugs. 2009; 7(4):605–23. https://doi.org/10.3390/md7040605 PMID: 20098602

59. Kovacs Z, Kekesi KA, Juhasz G, Barna J, Heja L, Lakatos R, et al. Non-adenosine nucleoside inosine, guanosine and uridine as promising antiepileptic drugs: a summary of current literature. Mini Rev Med Chem. 2015; 14(13):1033–42. PMID: 25382017

60. Kovács Z, Kékesi KA, Dobolyi Á, Lakatos R, Juhász G. Absence epileptic activity changing effects of non-adenosine nucleoside inosine, guanosine and uridine in Wistar Albino Glaxo Rijswijk rats. Neuroscience. 2015; 300:593–608. https://doi.org/10.1016/j.neuroscience.2015.05.054 PMID: 26037802

61. Lewin E, Bleck V. Effect of inosine on seizures induced with pentylenetetrazole, bicuculline, or picrotoxin. Epilepsia. 1985; 26(3):258–61. PMID: 3924588

62. Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014; 71(2):141–50. https://doi.org/10.1001/jamaneurol.2013.5528 PMID: 24366103

63. Paganoni S. ALSUntangled No. 37: Inosine*. Amytroph Lat Scl Fr. 2017; 18(3–4):309–12.

64. Guillard Robert. Culture of phytoplankton for feeding marine invertebrates. In: Smith WL, Chanley MH, editors. Culture of Marine Invertebrate Animals: Proceedings— 1st Conference on Culture of Marine Invertebrate Animals Greenport. Boston, MA: Springer US; 1975. p. 29–60.

65. Challal S, Queiroz EF, Debrus B, Kloeti W, Guillarme D, Gupta MP, et al. Rational and efficient preparative isolation of natural products by MPLC-UV-ELSD based on HPLC to MPLC gradient transfer. Planta Med. 2015; 81(17):1636–43. https://doi.org/10.1055/s-0035-1545912 PMID: 25922910

66. Westerfield. The zebrafish book. A guide for the laboratory use of zebrafish (*Danio rerio*). 4th ed Eugene, Oregon: University of Oregon. 2000.

67. Baraban SC, Taylor MR, Castro PA, Baier H. Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience. 2005; 131(3):759–68. https://doi.org/10.1016/j.neuroscience.2004.11.031 PMID: 15730879

68. Maes J, Verlooy L, Buenafe OE, de Witte PAM, Esguerra CV, Crawford AD. Evaluation of 14 organic solvents and carriers for screening applications in zebrafish embryos and larvae. Plos One. 2012; 7 (10):e43850. https://doi.org/10.1371/journal.pone.0043850 PMID: 23082109

69. Ingebrigtsen RA, Hansen E, Andersen JH, Eilertsen HC. Light and temperature effects on bioactivity in diatoms. J Appl Phycol. 2016; 28:939–50. https://doi.org/10.1007/s10811-015-0631-4 PMID: 27057087